Can I Take Quercetin with Zetia (Ezetimibe)?

Why Women Are Asking This Question

Cholesterol management in women is not the same conversation it is for men. Women tend to develop cardiovascular disease roughly a decade later than men, but their risk rises sharply after menopause. Data from the American Heart Association show that cardiovascular disease is the leading cause of death in American women, responsible for about one in three female deaths each year. At the same time, more women are reaching for quercetin, a plant flavonoid sold as an anti-inflammatory, antihistamine, and immune supplement.

Zetia (ezetimibe 10 mg daily) is the go-to non-statin cholesterol drug for women who cannot tolerate statins, women in perimenopause whose LDL is rising as estrogen falls, and women with PCOS or hypothyroidism managing complex lipid profiles. Quercetin is one of the most popular supplements in that same demographic. The overlap is predictable, and the interaction question is legitimate.

What Is Ezetimibe and How Does It Work?

Ezetimibe blocks the Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestinal brush border. That protein is the main gate through which dietary and biliary cholesterol enters your body. By blocking NPC1L1, ezetimibe reduces LDL cholesterol by approximately 18-20% as monotherapy, or by an additional 20-25% when added to a statin. After absorption, ezetimibe is glucuronidated in the intestinal wall and liver to its active form, ezetimibe-glucuronide, which undergoes extensive enterohepatic recycling. That recycling loop, controlled largely by hepatic uptake transporters OATP1B1 and OATP1B3 and the efflux transporter MRP2, is exactly where quercetin may interfere.

What Is Quercetin and Why Do Women Take It?

Quercetin is a polyphenol found in onions, apples, kale, and berries. As a supplement, women take it for:

• Seasonal allergy relief (it inhibits histamine release from mast cells)
• Reducing systemic inflammation, particularly in PCOS and endometriosis
• General antioxidant support during perimenopause
• Potential cardiovascular benefit, since some in-vitro data suggest it may reduce LDL oxidation

A 2021 meta-analysis in Frontiers in Pharmacology found that quercetin supplementation significantly reduced LDL cholesterol in human trials, though the effect size was modest and most trials were short-term. This cholesterol-adjacent activity is part of why women already on ezetimibe wonder whether quercetin adds benefit or creates problems.

The Actual Interaction: Pharmacokinetics, Not Pharmacodynamics

The quercetin-ezetimibe interaction is pharmacokinetic, not pharmacodynamic. That distinction matters.

A pharmacodynamic interaction would mean the two substances work on the same biological target simultaneously, creating either additive benefit or competing effects. That is not what happens here. Both agents may reduce LDL, but through entirely separate mechanisms (NPC1L1 blockade for ezetimibe; uncertain and multi-target effects for quercetin), so there is no direct antagonism or dangerous amplification of effect at the action site.

The pharmacokinetic concern is transport-level interference.

How Quercetin Affects Drug Transporters

Quercetin is a known inhibitor of several drug transporters:

• OATP1B1 and OATP1B3: Hepatic uptake transporters that pull ezetimibe-glucuronide from portal blood into liver cells for recycling. Quercetin inhibits these transporters in vitro and in some animal models.
• MRP2 (ABCC2): An efflux transporter in both intestinal cells and liver that exports ezetimibe metabolites back into the gut lumen for enterohepatic recycling.
• P-glycoprotein (P-gp): Quercetin inhibits P-gp, which could reduce intestinal efflux of ezetimibe and increase absorption.

An in-vitro study published in the European Journal of Pharmacology demonstrated that quercetin concentrations achievable in portal blood after high-dose supplementation significantly inhibited OATP1B1-mediated transport of substrates including statin-class drugs and their metabolites. Ezetimibe-glucuronide is an OATP1B1 substrate, making this finding directly relevant.

What Happens in Practice: Ezetimibe Exposure May Rise

When OATP1B1 and MRP2 are inhibited by quercetin, the enterohepatic recycling of ezetimibe-glucuronide is disrupted. Less active metabolite gets taken up by the liver for recycling, and potentially more stays in systemic circulation. The net theoretical effect is a modest increase in ezetimibe and ezetimibe-glucuronide plasma exposure (area under the curve, AUC).

A 2020 pharmacokinetic review in Drug Metabolism and Disposition confirmed that quercetin, at doses above 500 mg, produces portal-vein concentrations sufficient to inhibit clinically relevant hepatic uptake transporters in humans, not just in cell lines. This is the evidence that elevates the interaction from "theoretical" to "plausible."

The critical question is whether increased ezetimibe exposure translates to harm. Ezetimibe has a wide therapeutic index. Higher plasma levels are more likely to produce marginally greater LDL lowering than toxicity. Serious ezetimibe adverse effects (myopathy, hepatotoxicity) are rare even at standard doses, and no case reports document harm from quercetin co-administration specifically.

Is There a Direct Human Trial?

Honest answer: no. There is no randomized controlled trial measuring ezetimibe pharmacokinetics in humans given quercetin simultaneously. The evidence is built from:

1. In-vitro transporter inhibition data
2. Animal pharmacokinetic studies
3. Human pharmacokinetic data on quercetin's transporter effects with other OATP1B1 substrates (notably some statins)
4. Ezetimibe's known transporter substrate status

This is an extrapolated interaction, not a directly studied one. Women deserve to know that distinction. The absence of a human ezetimibe-quercetin trial reflects the broader pattern of under-studied drug-supplement interactions in women's health research.

Does Quercetin Change Ezetimibe's Cholesterol-Lowering Effect?

Possibly, in either direction.

If quercetin inhibits hepatic uptake of ezetimibe-glucuronide, it could disrupt the enterohepatic cycle that delivers active drug back to the intestinal lumen. Less drug recycled to the gut means less NPC1L1 inhibition, which could theoretically reduce efficacy. Conversely, if systemic AUC rises due to reduced hepatic clearance, some of that extra exposure may still reach intestinal tissue via circulation and maintain or improve effect.

A 2016 study in Lipids in Health and Disease found that quercetin at 150 mg/day for 8 weeks reduced LDL cholesterol by a mean of 4.7 mg/dL in adults with dyslipidemia. Combined with ezetimibe's own LDL reduction, additive lipid lowering is a plausible outcome rather than loss of efficacy, though this remains unstudied.

Women with PCOS often have atherogenic dyslipidemia with elevated triglycerides and small dense LDL. Quercetin's anti-inflammatory properties may complement ezetimibe's lipid-specific effect in this population, but clinical evidence specific to PCOS and this combination does not yet exist.

Women-Specific Physiology: Why This Interaction May Hit Differently

The Menstrual Cycle and Drug Transporters

Estrogen and progesterone both modulate hepatic transporter expression. OATP1B1 activity varies across the menstrual cycle in women of reproductive age, meaning the magnitude of any quercetin-induced transporter inhibition may differ between follicular and luteal phases. No trial has measured this directly for ezetimibe. This is an acknowledged evidence gap.

Perimenopause and Post-Menopause

This is where ezetimibe use in women spikes. Estrogen suppresses LDL receptor activity in ways that protect cardiovascular health during reproductive years. When estrogen falls in perimenopause, LDL often rises by 10-15% within two to three years of the menopause transition. The SWAN study documented that LDL cholesterol increased by a mean of 9 mg/dL across the menopause transition, independent of age and BMI. Women starting ezetimibe at this stage are often also starting supplement regimens that include quercetin for joint pain, allergy relief, or inflammation. The co-administration scenario is common.

PCOS

Women with PCOS have a two-to-three-fold higher prevalence of dyslipidemia than age-matched controls. ACOG Practice Bulletin No. 194 on PCOS recommends lipid screening for all women with PCOS every 3-5 years, or more frequently with additional cardiovascular risk factors. Ezetimibe may be used when statin therapy is not tolerated or not preferred. Quercetin appears in PCOS supplement stacks for its potential insulin-sensitizing and anti-androgen properties. This population is at particular risk of unmonitored combination.

Hypothyroidism

Subclinical and overt hypothyroidism are more common in women and independently worsen lipid profiles. Women on levothyroxine and ezetimibe who add quercetin face a three-way pharmacokinetic consideration: quercetin may also modestly inhibit thyroid hormone uptake transporters in the liver, potentially affecting T4 metabolism. Data are limited, but it is another reason to flag the combination to your prescriber.

Pregnancy and Lactation: Non-Negotiable Stops

Ezetimibe in Pregnancy

Ezetimibe is contraindicated in pregnancy. Cholesterol and its derivatives are required for fetal development, including steroid hormone synthesis and cell membrane formation. Inhibiting cholesterol absorption during pregnancy carries a theoretical risk of fetal harm.

The FDA classifies ezetimibe as Pregnancy Category X when used with a statin, and the prescribing information states ezetimibe should be discontinued as soon as pregnancy is recognized. As monotherapy, ezetimibe is listed as Pregnancy Category C in older classification systems, but current guidance from most clinicians is to avoid it throughout pregnancy given the lack of reassuring human data and the theoretical concern.

If you are planning a pregnancy and taking ezetimibe, discuss a stop date with your clinician. Reliable contraception is required during ezetimibe therapy if pregnancy would be unacceptable. ACOG guidance on preconception counseling emphasizes reviewing all lipid-lowering agents before conception, including ezetimibe.

Quercetin in Pregnancy

Human data on quercetin supplementation in pregnancy are insufficient to establish safety. Animal studies at high doses have raised concerns about quercetin's potential mutagenic effects, though these doses far exceed typical supplement use. The precautionary recommendation is to avoid quercetin supplements during pregnancy, though food-source quercetin (onions, apples) is not a concern.

Ezetimibe and Lactation

Ezetimibe transfers into rat milk in animal studies. Human lactation data are absent. Because cholesterol is essential for infant brain and neurological development, any agent that reduces cholesterol absorption is a theoretical concern during breastfeeding. Most clinicians advise avoiding ezetimibe while breastfeeding and considering a postpartum lipid plan that prioritizes dietary and lifestyle modification first.

Quercetin and Lactation

Quercetin passes into breast milk in animal models. Human data are insufficient to determine safe supplement doses during lactation. Food-source intake is not a concern.

Who Should Be Cautious vs. Who Can Proceed

The following framework is based on available pharmacokinetic evidence and clinical judgment from the WomanRx editorial board. It is not validated in a prospective trial.

Lower-Concern Profile

You are a lower-concern candidate for taking quercetin alongside ezetimibe if:

• You are post-menopausal, not pregnant, and not planning pregnancy
• Your quercetin dose is at or below 500 mg daily from a single daily supplement
• You are not taking any other OATP1B1-sensitive drugs (e.g., certain statins, repaglinide)
• Your LDL response to ezetimibe has been stable for at least 12 weeks before adding quercetin
• You inform your prescriber and schedule a lipid recheck 6-12 weeks after starting quercetin

Higher-Concern Profile

Use caution and get explicit clinician sign-off if:

• You take ezetimibe plus a statin (particularly atorvastatin, rosuvastatin, or simvastatin, all of which are OATP1B1 substrates, adding another layer of transporter interaction)
• You use quercetin at doses above 1,000 mg daily
• You have hepatic impairment, which already slows ezetimibe glucuronidation
• You have poorly controlled LDL and any loss of ezetimibe efficacy would increase cardiovascular risk meaningfully
• You are in the trying-to-conceive window

When to Stop and Reassemble

Stop quercetin and recheck your LDL if:

• Your LDL rises unexpectedly by more than 15 mg/dL after starting quercetin (possible transporter disruption reducing ezetimibe efficacy)
• Your LDL drops sharply below target (possible additive effect requiring dose reassessment)
• You develop unexplained muscle aches, GI symptoms, or liver enzyme elevation

Dose-Timing Strategies: Does Separating the Doses Help?

Separating ezetimibe and quercetin by time has theoretical appeal but limited practical evidence. The transporter inhibition from quercetin is not simply a luminal event; it affects hepatic transporters that are relevant for hours after absorption. A two-hour separation, sometimes suggested for grapefruit-drug interactions, is unlikely to fully protect the enterohepatic recycling of ezetimibe-glucuronide from quercetin taken earlier in the day.

Taking ezetimibe in the morning and quercetin with an evening meal is a reasonable precaution that avoids peak simultaneous intestinal concentrations. Ezetimibe can be taken at any time of day without food requirements.

The prescribing information for Zetia states that ezetimibe can be taken at any time of day, with or without food, and that co-administration with bile acid sequestrants (which do affect absorption timing) warrants at least a 2-hour separation. No specific timing guidance for quercetin exists in the label.

Monitoring: What to Track and When

If you decide to continue both, here is a practical monitoring plan:

| Timepoint | Action | |---|---| | Before starting quercetin | Baseline fasting lipid panel; record current LDL | | 6-8 weeks after starting quercetin | Repeat fasting lipid panel | | 12 weeks | Liver enzyme check if clinically indicated | | Ongoing, every 6-12 months | Routine lipid monitoring as recommended for ezetimibe therapy |

The National Lipid Association recommends fasting lipid panels 4-12 weeks after any change in lipid-lowering therapy to confirm efficacy. Adding a new supplement with transporter-interaction potential qualifies as a change worth monitoring.

What If You Are Already Taking Both?

Do not panic, and do not stop either abruptly without speaking to your clinician. Here is what to do:

1. Tell your prescriber or pharmacist that you are taking quercetin alongside ezetimibe, and at what dose.
2. Request a fasting lipid panel if more than 8 weeks have passed since your last one.
3. Review whether your quercetin dose can be reduced to 500 mg daily or less while still meeting your reason for taking it.
4. Ask whether your ezetimibe LDL response has been on track. If your LDL has been stable and on target, the practical risk of transporter disruption appears low.

A 2022 review in the Journal of Clinical Lipidology noted that drug-supplement interactions at the transporter level are clinically underappreciated and that routine medication reviews should specifically ask about flavonoid supplement use given their transporter inhibitory profile. Most clinicians do not ask. You may need to volunteer this information.

The Evidence Gap: What We Still Don't Know

Women have been under-represented in pharmacokinetic drug-supplement interaction studies. Nearly all in-vitro and animal data on quercetin-transporter inhibition come from research not specifically designed to study women, hormonal fluctuations, or life-stage differences in transporter expression.

What we do not know:

• Whether the magnitude of quercetin's OATP1B1 inhibition differs between pre-menopausal and post-menopausal women due to estrogen's known regulatory effect on OATP expression
• Whether the interaction is clinically significant at the 500 mg quercetin doses most women use (versus the 1,000-2,000 mg doses in in-vitro models)
• Whether there is a meaningful effect on lipid outcomes from long-term co-administration

This does not mean the combination is dangerous. It means the absence of specific human women's-health data requires both transparency and reasonable precaution.

Other Supplement Interactions to Know About with Ezetimibe

Quercetin is not the only supplement worth flagging if you take Zetia. For completeness:

• Berberine: Also inhibits OATP1B1 and has independent LDL-lowering effects. The combination may produce unpredictably additive cholesterol reduction and warrants lipid monitoring.
• Red yeast rice: Contains monacolin K, chemically identical to lovastatin. Combined with ezetimibe, this creates an unregulated statin-ezetimibe combination without medical supervision.
• Fish oil (omega-3): No significant transporter interaction with ezetimibe. Generally compatible.
• Fiber supplements (psyllium): May reduce ezetimibe absorption slightly if taken simultaneously. Space by at least 2 hours.